Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/200884
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Westin, Jason R. | - |
dc.contributor.author | Locke, Frederick L. | - |
dc.contributor.author | Dickinson, Michael | - |
dc.contributor.author | Ghobadi, Armin | - |
dc.contributor.author | Elsawy, Mahmoud | - |
dc.contributor.author | Van Meerten, Tom | - |
dc.contributor.author | Miklos, David B. | - |
dc.contributor.author | Ulrickson, Matthew L. | - |
dc.contributor.author | Perales, Miguel Angel | - |
dc.contributor.author | Farooq, Umar | - |
dc.contributor.author | Wannesson, Luciano | - |
dc.contributor.author | Leslie, Lori | - |
dc.contributor.author | Kersten, Marie José | - |
dc.contributor.author | Jacobson, Caron A. | - |
dc.contributor.author | Pagel, John M. | - |
dc.contributor.author | Wulf, Gerald | - |
dc.contributor.author | Johnston, Patrick | - |
dc.contributor.author | Rapoport, Aaron P. | - |
dc.contributor.author | Du, Linqiu | - |
dc.contributor.author | Vardhanabhuti, Saran | - |
dc.contributor.author | Filosto, Simone | - |
dc.contributor.author | Shah, Jina | - |
dc.contributor.author | Snider, Julia T. | - |
dc.contributor.author | Cheng, Paul | - |
dc.contributor.author | To, Christina | - |
dc.contributor.author | Oluwole, Olalekan O. | - |
dc.contributor.author | Sureda, Anna | - |
dc.date.accessioned | 2023-07-19T09:59:53Z | - |
dc.date.available | 2023-07-19T09:59:53Z | - |
dc.date.issued | 2023-03-31 | - |
dc.identifier.issn | 1557-3265 | - |
dc.identifier.uri | http://hdl.handle.net/2445/200884 | - |
dc.description.abstract | Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients >= 65 years in ZUMA-7. Patients and Methods: Patients with LBCL refractory to or relapsed <= 12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported out-comes (PROs).Results: Fifty-one and 58 patients aged >= 65 years were random-ized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade >= 3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients >= 65 and <65 years. Conclusions: Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients >= 65 years with R/R LBCL. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Association for Cancer Research (AACR) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1158/1078-0432.CCR-22-3136 | - |
dc.relation.ispartof | Clinical Cancer Research, 2023, vol. 29, num. 10, p. 1894-1905 | - |
dc.relation.uri | https://doi.org/10.1158/1078-0432.CCR-22-3136 | - |
dc.rights | cc by (c) Westin, Jason R. et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Persones grans | - |
dc.subject.classification | Immunoteràpia | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Older people | - |
dc.subject.other | Immunotheraphy | - |
dc.title | Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-06-21T08:22:13Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36999993 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ccr-22-3136.pdf | 4.96 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License